A
Altesa BioSciences
Altesa Biosciences, Inc., is a clinical-stage biopharmaceutical company developing drugs to treat RNA viruses, which are responsible for 80% of viral diseases worldwide
About Altesa BioSciences
Altesa BioSciences, Inc. is a clinical stage biopharmaceutical company focused on developing drugs to treat RNA viruses, which are responsible for 80% of viral diseases globally. The company targets a range of respiratory viruses including Rhinovirus, Influenza, Respiratory Syncytial Virus (RSV), as well as other significant viral threats like Dengue, Yellow Fever, Ebola, and SARS-CoV-2 (COVID-19). Altesa BioSciences operates in the biopharmaceutical market, serving healthcare providers, patients, and research institutions. The company's business model revolves around the research and development (R&D) of antiviral drugs, leveraging a Sponsored Research Agreement with Emory DRIVE to access a robust R&D pipeline and industry-trained scientists. Revenue is generated through the development and eventual commercialization of these antiviral treatments. The leadership team includes experts with extensive experience in virology, biotechnology, and pharmaceutical development, such as Brett P. Giroir, MD, and George R. Painter, PhD. The company aims to make a significant impact on global health by providing safe and effective treatments for a variety of pathogenic viruses.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2026 | $75M | $300M | Pitango Venture Capital · Sanofi · Medicxi · Forbion Capital Partners | ↗ |
| SERIES AOther financing | Jul 2023 | $35M | $140M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Altesa BioSciences is 3.7K monthly website visits, up 27.6% over the last three months. Altesa BioSciences's team grew 300% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Altesa BioSciences in the College Park ecosystem
The Altesa BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Forbion Capital Partners
Pitango Venture Capital
Sanofi
Medicxi
Atlantic Partners Asia
Source: Dealroom Talent Intelligence.
See Altesa BioSciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








